Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol

• 2024

  Sign in to bookmark this resource.

  Sign in
• Narmeen Mallah; Sonia Ares-Gómez; Jacobo Pardo-Seco; Alberto Malvar-Pintos; María-Isolina Santiago-Pérez; Olaia Pérez-Martínez
PMID: 38738683DOI: https://dx.doi.org/10.1080/21645515.2024.2348135

---

Access Resources

• Journal ArticleEN

About

The NIRSE-GAL study in Galicia, Spain, aims to assess the effectiveness of nirsevimab in preventing hospitalizations due to Respiratory Syncytial Virus (RSV) in infants. It describes a three-year plan starting from 2023, focusing on infants born during the RSV season and those at high risk. The study will monitor RSV cases and evaluate nirsevimab's impact on healthcare use and respiratory conditions like wheezing and asthma. Data will be collected through digital health systems, with findings shared via publications and conferences to inform public health decisions about RSV prevention strategies.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Nirsevimab Library

Keywords: Child; Epidemiology; Hospitalization; Infant; Infant, Newborn; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Spain; Immunization Programs; Palivizumab; Antibodies, Monoclonal, Humanized; Public Health Surveillance

Institutions: Instituto de Investigación Sanitaria; World Health Organization (WHO); University of Santiago de Compostela; Instituto de Salud Carlos III

---

More like this

Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain 2024 · University Carlos III, BioMad, Fisabio-Public Health, Catholic University of Valencia, Instituto de Salud Carlos III, Weber Foundation Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting 2024 · Fisabio-Public Health, Instituto de Salud Carlos III, University of Valencia Pandemic Planning, Response, and Recovery for Pediatricians: A Focus on Health Equity and Social Determinants of Health 2024 · Children's National Hospital, George Washington University

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---